Neurocrine Biosciences, Inc. NBIX
NASDAQ · United States · Health Technology
$141.84+3.49 (+2.52%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
| Quarter | Report date | Actual EPS | Estimated EPS | EPS surprise | Actual revenue | Revenue surprise | Price reaction |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2026-07-30 | 1.39 | 1.65 | -15.7% | $959.00M | +7.6% | -7.7%$180.79→$166.80 |
| Q1 2026 | 2026-05-05 | 1.41 | 1.28 | +10.2% | — | — | +9.7%$134.07→$147.02 |
| Q4 2025 | 2026-02-11 | 1.88 | 2.30 | -18.3% | — | — | -10.6%$137.65→$123.10 |
| Q3 2025 | 2025-10-28 | 2.17 | 2.07 | +4.8% | — | — | -7.3%$148.94→$138.02 |
| Q2 2025 | 2025-07-30 | 1.65 | 1.50 | +10.0% | — | — | — |
| Q1 2025 | 2025-05-05 | 0.70 | 1.09 | -35.8% | — | — | — |
| Q4 2024 | 2025-02-06 | 1.69 | 1.93 | -12.4% | — | — | — |
| Q3 2024 | 2024-10-30 | 1.81 | 1.82 | -0.5% | — | — | — |
The price reaction is the change from the last close before the announcement date to the first close after it - the report may land before the open, during the session or after the close, so this window covers all three. Not investment advice.